Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biomarker and clinical evaluation of bevacizumab (Avastin) to determine the role of nitric oxide in anti-VEGF [vascular epidermal growth factor] therapy.

Trial Profile

Biomarker and clinical evaluation of bevacizumab (Avastin) to determine the role of nitric oxide in anti-VEGF [vascular epidermal growth factor] therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Solid tumours
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 09 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top